Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Not Confirmed
Not Confirmed
01-02 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
31 March-01 April, 2025
Plastics Recycling EUPlastics Recycling EU
Industry Trade Show
Not Confirmed
01-02 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
06 Mar 2025
// BUSINESSWIRE
05 Mar 2025
// BUSINESSWIRE
24 Feb 2025
// BUSINESSWIRE
14 Feb 2025
// BUSINESSWIRE
04 Feb 2025
// BUSINESSWIRE
30 Jan 2025
// BUSINESSWIRE
Details:
Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Lead Product(s): Self-amplifying mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Kostaive
Study Phase: Approved FDFProduct Type: Vaccine
Recipient: CSL
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 14, 2025
Lead Product(s) : Self-amplifying mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : CSL
Deal Size : Inapplicable
Deal Type : Inapplicable
EU Approves CSL, Arcturus’ KOSTAIVE®, First Self-Amplifying mRNA COVID Vaccine
Details : Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Product Name : Kostaive
Product Type : Vaccine
Upfront Cash : Inapplicable
February 14, 2025
Details:
ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IIProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2025
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arcturus Begins Dosing in Phase 2 Cystic Fibrosis, OTC Deficiency Studies
Details : ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with Cystic Fibrosis.
Product Name : ARCT-032
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 06, 2025
Details:
ARCT-2304 is a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus.
Lead Product(s): ARCT-2304
Therapeutic Area: Infections and Infectious Diseases Brand Name: ARCT-2304
Study Phase: IND EnablingProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2024
Lead Product(s) : ARCT-2304
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Arcturus Gets FDA Clearance for H5N1 Flu Vaccine Clinical Trial
Details : ARCT-2304 is a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus.
Product Name : ARCT-2304
Product Type : Vaccine
Upfront Cash : Not Applicable
November 11, 2024
Details:
Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Lead Product(s): Self-amplifying mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Kostaive
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2024
Lead Product(s) : Self-amplifying mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan Approves CSL and Arcturus Updated mRNA COVID-19 Vaccine for JN.1 Strain
Details : Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Product Name : Kostaive
Product Type : Vaccine
Upfront Cash : Not Applicable
September 13, 2024
Details:
ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 03, 2024
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arcturus Receives FDA Clearance For ARCT-032 Inhaled mRNA Therapeutic For Cystic Fibrosis
Details : ARCT-032 is an inhaled investigational mRNA therapeutic designed to express normal functional CFTR in the lungs of individuals with Cystic Fibrosis.
Product Name : ARCT-032
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 03, 2024
Details:
LUNAR-OTC (ARCT-810) is an intravenously administered mRNA therapy utilizing company’s LUNAR delivery platform to deliver OTC mRNA to hepatocytes for treating ornithine transcarbamylase deficiency.
Lead Product(s): ARCT-810
Therapeutic Area: Genetic Disease Brand Name: ARCT-810
Study Phase: Phase IIProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2024
Lead Product(s) : ARCT-810
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arcturus Provides Updates on OTC Deficiency and CF Programs
Details : LUNAR-OTC (ARCT-810) is an intravenously administered mRNA therapy utilizing company’s LUNAR delivery platform to deliver OTC mRNA to hepatocytes for treating ornithine transcarbamylase deficiency.
Product Name : ARCT-810
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 01, 2024
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 28, 2024
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
Details : ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Product Name : ARCT-032
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 28, 2024
Details:
The collaboration with Arcturus Therapeutics, to evaluate best-in-class, self-amplifying mRNA vaccines for the treatment of patients suffering from neoplasms.
Lead Product(s): mRNA Based Therapy
Therapeutic Area: Oncology Brand Name: mRNA Based Therapy
Study Phase: Discovery PlatformProduct Type: Vaccine
Recipient: Achilles Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 22, 2024
Lead Product(s) : mRNA Based Therapy
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Achilles Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Achilles and Arcturus Collaborate on Second-Generation mRNA Cancer Vaccines
Details : The collaboration with Arcturus Therapeutics, to evaluate best-in-class, self-amplifying mRNA vaccines for the treatment of patients suffering from neoplasms.
Product Name : mRNA Based Therapy
Product Type : Vaccine
Upfront Cash : Undisclosed
May 22, 2024
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Brand Name: ARCT-032
Study Phase: Phase IProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 22, 2024
Lead Product(s) : ARCT-032
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arcturus Receives Orphan Medicinal Product Designation for ARCT-032 in Cystic Fibrosis
Details : ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Product Name : ARCT-032
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 22, 2024
Details:
ARCT-154 is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Brand Name: LUNAR-COV19
Study Phase: ApprovedProduct Type: Vaccine
Sponsor: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Lead Product(s) : ARCT-154
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : CSL
Deal Size : Not Applicable
Deal Type : Not Applicable
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154,...
Details : ARCT-154 is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Product Name : LUNAR-COV19
Product Type : Vaccine
Upfront Cash : Not Applicable
November 28, 2023
ABOUT THIS PAGE